Type 2 Diabetes Trial, Not Yet Recruiting NCT07424430 Sponsor: LMC Diabetes & Endocrinology Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07424430
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

For people with Type 2 Diabetes:

  • People who have been diagnosed with Type 2 diabetes for at least 1 year
  • People whose blood sugar control measurement (HbA1c) was 6.5% or higher before the study start date
  • People who started semaglutide or another blood sugar-lowering medication before January 1st, 2023
  • People who have been seen by a specialist diabetes doctor (endocrinologist) within the last 18 months
  • People who have at least one blood sugar control measurement (HbA1c) taken within roughly 6 months before the study start date
  • People who have given consent for their medical record data to be used for research

For people with Obesity (without Type 2 Diabetes):

  • People who are 18 years of age or older
  • People with a BMI of 27 or higher
  • People whose blood sugar control measurement (HbA1c) was below 6.5% before the study start date
  • People who started semaglutide before January 1st, 2023
  • People who have been seen by a specialist diabetes doctor (endocrinologist) within the last 18 months
  • People who have at least one blood sugar control measurement (HbA1c) taken within roughly 6 months before the study start date
  • People who have given consent for their medical record data to be used for research

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have been diagnosed with Type 1 diabetes or a related condition called latent autoimmune diabetes in adults (LADA)
  • People with a Type 2 diabetes diagnosis (this applies to the obesity group only)
  • People who were pregnant when they started semaglutide or another blood sugar-lowering medication, or who became pregnant during the follow-up period
  • People with a personal or family history of a specific type of thyroid cancer called medullary thyroid carcinoma
  • People who are already taking part in another research study involving an experimental treatment or product
  • People whose kidney function was severely reduced (measured by a specific blood test called eGFR being below 15 mL/min/1.73m²) at the study start date (confirm with trial site)
  • People who used a GLP-1 medication other than semaglutide for more than 6 months after the study start date (applies to the Type 2 diabetes and obesity semaglutide groups)
  • People who used another blood sugar-lowering medication for more than 6 months after the study start date within the first year of taking semaglutide (applies to the Type 2 diabetes and obesity semaglutide groups)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (416) 645-2929

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
LMC Diabetes & Endocrinology Ltd.
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 April 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Change in HbA1c- 3 Years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov